MayoAZHemOncFellows
@az_onc
Followers
34
Following
0
Media
1
Statuses
31
Educational page for Hematology and Oncology Fellows. This site serves as a digital journal club and tumor board for Hematology and Oncology related topics.
Phoenix, AZ
Joined December 2019
The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff @sloan_kettering who have made this initiative possible. A few thoughts on what we have learned.
16
156
443
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? https://t.co/yC0zcr1Uob
@BloodAdvances
1
14
51
Excellent paper on AML The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
onlinelibrary.wiley.com
Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The accumulated experience of allografting in AML over the last four decades...
0
1
1
Mosunetuzumab: new bispecific antibody targeting CD20/CD3 and is aimed for approval in R/R DLBCL or FL https://t.co/LyjvqsbGmL
0
0
0
Phase 2 study of cerdulatinib (JAK/SYK inhibitor) in R/R T cell lymphoma https://t.co/auFUWkf6B5
0
0
0
PET directed therapy for early stage DLBCL: https://t.co/bhQSgdtcoL
0
0
0
Zuma-2: CD19 CAR-T therapy in R/R MCL https://t.co/FSLtEtT6yd
0
0
0
Update on KEYNOTE 522. pCR improved when adding pembro to neoadjuvant therapy for TNBC https://t.co/Qs5gGAiNhW
0
0
0
Abstract GS1-07 at SABCS: overall survival effect of capecitabine therapy for โtriple negativeโ disease. Part of NCCN as well
0
0
0
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
0
0
0
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | NEJM
nejm.org
Patients with human epidermal growth factor receptor 2 (HER2)โpositive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment ...
0
0
0
Analysis based on outcomes in the ISPY2. Burden to predict likelihood of recurrence or death in the 10 years following surgery. https://t.co/0IbSu0G9fS
0
0
0
Online model for clinicians to predict late distant metastasis for women with ER-positive breast cancer who are recurrence-free 5 years after endocrine therapy. https://t.co/sTOlzE5QWG
0
0
0
1/16 Let's start off 2020 with some #Bacteremia myth๐ฅ!! Some questions answered here: Do fevers predict bacteremia? Can you predict when someone will have an ESBL bacteremia? I learned a lot preparing this review, I hope you do too #MedTwitter #IDTwitter #MedEd
17
285
665
Great Collaboration, thanks to all!Global GermCellCa Group: 51 patients with CS I NSGCT who experienced a relapse after adj BEP: โญ๏ธ63% of relapses occurred during the first 2 years! โญ๏ธLate relapses as a predictor of poor outcome! https://t.co/miw5hG5iYJ
0
3
6
@az_onc see below from SV Rajkumar
๐ง๐ผ๐ฝ ๐ญ๐ฌ ๐บ๐๐ฒ๐น๐ผ๐บ๐ฎ ๐ฝ๐ฎ๐ฝ๐ฒ๐ฟ๐ ๐ผ๐ณ ๐๐ต๐ฒ ๐๐ฒ๐ฎ๐ฟ 2019 was a great year for myeloma. Iโve listed my Top 10 with links to the paper. #MyelomaVR @mtmdphd @Rfonsi1 @grpetersen1 @NorthTxMSG @Mohty_EBMT @SagarLonialMD Thread/ Countdown below! ๐
0
1
1
ICYMI: #Levofloxacin #prophylaxis in patients with newly diagnosed #myelomaโresults from the phase 3 TEAMM study
thelancet.com
Addition of prophylactic levofloxacin to active myeloma treatment during the first 12 weeks of therapy significantly reduced febrile episodes and deaths compared with placebo without increasing...
0
5
6